EDAP TMS S.A. Completes FDA Q&A Session For Its Ablatherm-HIFU Pre-Market Approval Application

Published: Mar 20, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LYON, France, March 20, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has completed its response to questions from the FDA regarding the Company's Ablatherm-HIFU Pre-Market Approval ("PMA") application, closing this step within the U.S. Food and Drug Administration ("FDA") review process.

Help employers find you! Check out all the jobs and post your resume.

Back to news